OpportunityTitle: Pediatric Preclinical Testing Consortium: Research Programs (U01)
AdditionalInformationOnEligibility: Other Eligible Applicants include the following:   Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Non-domestic (non-U.S.) Entities (Foreign Organizations); Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Description: This Funding Opportunity Announcement (FOA) is for Research Programs for in vivo and in vitro testing of the activity of pediatric anticancer drug candidates. These Research Programs are the fundamental part of the Pediatric Preclinical Testing Consortium (PPTC) initiative, which also includes a PPTC Coordinating Center (supported under RFA-CA-14-019). The main goal for PPTC is to develop a rigorous preclinical testing system for pediatric anticancer drug candidates and to generate reliable data that can be used to inform new agent prioritization decisions. This FOA invites applications for drug testing Research Programs focused on specific tumor types that are particularly relevant to pediatric oncology. Each application must propose only one testing Research Program from the following four types:Type A: Research Program for leukemia in vivo testing;Type B: Research Program for tumors of central nervous system (CNS) in vivo testing; Type C: Research Program for other (non-CNS) solid tumors testing in vivo; and Type D: Research Program for in vitro testing.Applicants may propose Research Programs of more than one type but only through separate applications for each. Applicants proposing in vivo testing programs must be capable of quantitative assessment of tumor regression and time to event for 6 to 10 new agents (or combinations of agents) annually across relevant, well-characterized preclinical models. All applicants are expected to have substantial expertise regarding the biology and therapeutic opportunities for the tumor types that they propose to study. The PPTC Research Program Awardees will be required to collaborate closely with the PPTC Coordinating Center.
GrantorContactEmailDescription: If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
GrantorContactText: NIH OER Webmaster &lt;br/&gt;FBOWebmaster@OD.NIH.GOV &lt;br/&gt;